• Mutation; HGNC; HGNC:7562; MYD88; Simple; p.Leu252Pro (c.755T>C)(p.Leu265Pro, c.794T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Hemizygous (from parent cell line).
  

PubMed=25382610; DOI=10.1038/bcj.2014.74; PMCID=PMC5424099
Kasyapa S. Chitta, Aneel Paulus, Thomas R. Caulfield, Sharoon Akhtar, Maja Kristin Kuranz Blake, Sikander Ailawadhi, Joshua Knight, Michael G. Heckman, Anthony B. Pinkerton, Asher A. Chanan-Khan;
Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenstroms macroglobulinemia.
Blood Cancer J. 4:e260.1-e260.10(2014)

PubMed=28548645; DOI=10.1038/bcj.2017.40; PMCID=PMC5518884
Aneel Paulus, Sharoon Akhtar, Hafiz Muhammad Yousaf, Alak Manna, Shumail Marshal Paulus, Yamima Bashir, Thomas R. Caulfield, Maja Kristin Kuranz Blake, Kasyapa S. Chitta, Xue Wang, Yan Asmann ...Show all 15 authors... , Roman Hudec, Wolfdieter Springer, Sikander Ailawadhi, Asher A. Chanan-Khan; Show fewer authors
Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.
Blood Cancer J. 7:e565.1-e565.11(2017)